EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Future Nanotechnology‐Based Strategies for Improved Management of Helicobacter pylori Infection

Mojtaba Kamankesh iD, Abbas Yadegar iD, Antoni Llopis-Lorente iD, Chenguang Liu, Ismaeil Haririan iD, Hamid Asadzadeh Aghdaei, Mohammad Ali Shokrgozar iD, Mohammad Reza Zali, Amir Hossein Miri iD, Mazda Rad-Malekshahi iD, Michael R Hamblin iD, Matthias G Wacker iD

Small · 2024

DOI: 10.1002/smll.202302532 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small, 2024. Verfasst von Mojtaba Kamankesh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Polymer Chemistry Department, School of Science, University of Tehran, PO Box 14155-6455, Tehran, 14144-6455, Iran. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 343 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Helicobacter pylori ( H. pylori ) is a recalcitrant pathogen, which can cause gastric disorders. During the past decades, polypharmacy‐based regimens, such as triple and quadruple therapies have been widely used against H. pylori . However, polyantibiotic therapies can disturb the host gastric/gut microbiota and lead to antibiotic resistance. Thus, simpler but more effective approaches should be developed. Here, some recent advances in nanostructured drug delivery systems to treat H. pylori infection are summarized. Also, for the first time, a drug release paradigm is proposed to prevent H. pylori antibiotic resistance along with an IVIVC model in order to connect the drug release profile with a reduction in bacterial colony counts. Then, local delivery systems including mucoadhesive, mucopenetrating, and cytoadhesive nanobiomaterials are discussed in the battle against H. pylori infection. Afterward, engineered delivery platforms including polymer‐coated nanoemulsions and polymer‐coated nanoliposomes are poposed. These bioinspired platforms can contain an antimicrobial agent enclosed within smart multifunctional nanoformulations. These bioplatforms can prevent the development of antibiotic resistance, as well as specifically killing H. pylori with no or only slight negative effects on the host gastrointestinal microbiota. Finally, the essential checkpoints that should be passed to confirm the potential effectiveness of anti‐ H. pylori nanosystems are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriHumansAnti-Bacterial AgentsDrug Resistance, BacterialDrug Therapy, CombinationNanotechnologyPolymers

Stichwörter der Autor:innen

H. pyloriantibiotic resistancelocal delivery systemsnanoformulationsequential drug release

Substanzen

Anti-Bacterial AgentsPolymers

Autor:innen und Institutionen

  • Polymer Chemistry Department, School of Science, University of Tehran, PO Box 14155-6455, Tehran, 14144-6455, Iran.
  • Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, 1985717411, Iran.
  • Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, CIBER de Bioingeniería, Biomateriales y Nanomedicin…
  • College of Marine Life Science, Ocean University of China, Qingdao, 266003, P.R. China.
  • Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, Iran.
  • Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, 1985717411, Iran.

ORCID-Profile: Mojtaba Kamankesh, Abbas Yadegar, Antoni Llopis-Lorente, Ismaeil Haririan, Mohammad Ali Shokrgozar, Amir Hossein Miri, Mazda Rad-Malekshahi, Michael R Hamblin, Matthias G Wacker

Zitieren

APA

Kamankesh, M., Yadegar, A., Llopis-Lorente, A., Liu, C., Haririan, I., Aghdaei, H. A., Shokrgozar, M. A., Zali, M. R., Miri, A. H., Rad-Malekshahi, M., Hamblin, M. R., & Wacker, M. G. (2024). Future Nanotechnology‐Based Strategies for Improved Management of Helicobacter pylori Infection. Small. https://doi.org/10.1002/smll.202302532

Vancouver

Kamankesh M, Yadegar A, Llopis-Lorente A, Liu C, Haririan I, Aghdaei HA, et al. Future Nanotechnology‐Based Strategies for Improved Management of Helicobacter pylori Infection. Small. 2024. doi:10.1002/smll.202302532

BibTeX
@article{Kamankesh2024,
  author = {Kamankesh, Mojtaba and Yadegar, Abbas and Llopis-Lorente, Antoni and Liu, Chenguang and Haririan, Ismaeil and Aghdaei, Hamid Asadzadeh and Shokrgozar, Mohammad Ali and Zali, Mohammad Reza and Miri, Amir Hossein and Rad-Malekshahi, Mazda and Hamblin, Michael R and Wacker, Matthias G},
  title = {Future Nanotechnology‐Based Strategies for Improved Management of Helicobacter pylori Infection},
  journal = {Small},
  year = {2024},
  doi = {10.1002/smll.202302532}
}
Kostenlos starten →